Search Results

% and a PFS of 4.3 months in the chemotherapy-alone arm. Grade 3 AEs in the ramucirumab arm included thrombocytopenia (15%), neutropenia (13%), fatigue (12%), and nausea (10%). Table 2 Ongoing Phase II and Phase III Trials in the United States of

.2% (3 stringent CRs, 10 VGPRs, 18 PRs). Median response duration was 7.4 months and median time to progression was 3.7 months; the estimated 1-year OS rate was 65%. 22 Adverse events reported included fatigue (39.6%), anemia (33.0%), nausea (29.2%), and

particularly at risk for experiencing high symptom burden and loss of muscle. 16 – 18 Patients with muscle loss often require hospital-level care to address treatment adverse effects and high symptom burden (eg, pain, fatigue, nausea). 19 Notably

%), anemia (13% vs 0%), and nausea (20% vs 2%). Crossover was allowed for the cetuximab/irinotecan group, and 48% of those patients received vemurafenib at time of progression. Of those who crossed over, the partial response rate was 17% and the stable

therapy. 5 , 6 , 9 Gastrointestinal irAEs frequently involve the colon, liver, and stomach and present with nausea, vomiting, diarrhea, rectal bleeding, or abdominal pain. 9 – 14 Rare gastrointestinal irAEs have been reported, such as esophagitis

(range, 1.9 to ≥21.8 months). The most common adverse effects with pembrolizumab were fatigue, pruritus, diarrhea, anorexia, constipation, nausea, rash, fever, cough, dyspnea, and musculoskeletal pain. Pembrolizumab also may be associated with immune

; chemotherapy is often associated with oral mucositis, nausea, and vomiting. 1 NCCN Guidelines Insights : Head and Neck Cancers, Version 2.2013 Version 2.2013 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines

alternative to the parenteral heparins. This is desirable for most patients with cancer, but may not be useful in patients whose gastrointestinal tract is unavailable because of disease involvement, surgery, radiation, or nausea. These agents also have easy

maternal grandmother, who was diagnosed and treated at 55 years of age. Review of systems was positive for intermittent headaches consistent with previous self-limiting migraines and occasional nausea without emesis, which had been diminishing in frequency

. Nonetheless, these multiagent regimens can cause more toxicity than single-agent chemotherapy, including nausea, vomiting, infection, and severe neuropathy. These toxicities can be debilitating, particularly with chronic administration. Efforts to include